Despite the widespread use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management of chronic kidney disease, their role in autosomal dominant polycystic kidney disease (ADPKD) remains unclear. This evidence concerns the gene SLC5A2 and autosomal dominant polycystic kidney disease.